Yabao Pharmaceutical released its 2026 interim report, with net profit attributable to the parent company reaching 178 million yuan, up 1.83% from the same period last year. During the reporting period, total operating revenue was 1.145 billion yuan, a slight year-on-year increase of 0.49%. Net cash inflow from operating activities was 353 million yuan, up 7.81% year-on-year. The company's latest asset-liability ratio stands at 15.03%, down 3.82 percentage points from the same period last year. Gross margin was 53.99%, rising for three consecutive quarters and up 1.43 percentage points year-on-year. Diluted earnings per share were 0.26 yuan, achieving five consecutive years of growth, with a year-on-year increase of 3.34%.
Yabao Pharmaceutical Group Co LtdNet profit attributable to parent increased 1.83% year-on-year, with gross margin rising for three consecutive quarters and diluted EPS achieving five consecutive years of growth.